November 2, 2020November 2, 2020

Libtayo Given FDA Priority Review for Advanced NSCLC With High PD-L1 Levels

News

The U.S. Food and Drug Administration (FDA) has granted priority review to an application seeking the approval of Libtayo (cemiplimab) as a first-line therapy for advanced non-small cell lung cancer (NSCLC) and high PD-L1 levels, according ... Read more

October 28, 2020October 28, 2020

Opdivo Combo Found to Extend Survival in Advanced Stomach, Esophageal Cancers

News

Adding Opdivo (nivolumab) to standard first-line chemotherapy significantly extends overall survival and delays disease progression or death in adults with inoperable advanced HER2-negative stomach cancer, esophageal adenocarcinoma, or gastroesophageal junction (GEJ) cancer, ... Read more